CapsulesClinical Overview
Lenvatinib Capsules (4mg) is an oral receptor tyrosine kinase inhibitor that selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, along with fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3, FGFR-4), PDGFR-alpha, KIT, and RET. Indicated for locally recurrent or metastatic, progressive radioactive iodine-refractory differentiated thyroid cancer, first-line treatment of unresectable hepatocellular carcinoma (HCC), and in combination with pembrolizumab for advanced endometrial carcinoma or advanced RCC.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Thyroid cancer: 24 mg once daily. HCC: 8 mg (<60 kg) or 12 mg (>=60 kg) once daily with or without food with water. Swallow capsules whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Severe hypertension, diarrhea, fatigue, decreased appetite, weight loss, arthralgia, proteinuria, palmar-plantar erythrodysesthesia. Rare/Severe: Cardiac dysfunction, arterial thromboembolism, hepatotoxicity, renal failure, and posterior reversible encephalopathy syndrome.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Control blood pressure prior to therapy; monitor BP weekly during the first 2 months and monthly thereafter. Perform routine urinalysis to check for proteinuria. Withhold lenvatinib prior to major surgical procedures due to impaired wound healing.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.